Skip to main content
IDEAYA Biosciences, Inc. logo

IDEAYA Biosciences, Inc. — Investor Relations & Filings

Ticker · IDYA ISIN · US45166A1025 LEI · 549300ULW08F62IJML11 US Manufacturing
Open in API
Filings indexed 466 across all filing types
Latest filing 2022-06-11 Director's Dealing
Country US United States of America
Listing US IDYA

About IDEAYA Biosciences, Inc.

https://www.ideayabio.com/

IDEAYA Biosciences, Inc. is a clinical-stage precision medicine oncology company focused on the discovery, development, and commercialization of targeted therapeutics for cancer. The company's primary scientific approach is synthetic lethality, an emerging class of precision medicine that targets cancer cells based on specific genetic alterations. IDEAYA develops potential first-in-class and best-in-class therapies for patient populations selected using molecular diagnostics. Its integrated platform combines capabilities in target and biomarker discovery with the development of small molecule and protein degrader therapeutics to address unmet needs in cancer treatment.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2022-06-11 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated June 9, 2022, by IDEAYA Biosciences, Inc. The content focuses on the submission of matters to a vote of security holders at the 2022 Annual Meeting of Stockholders, including detailed voting results for director elections and auditor ratification. This matches the description of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 4115 characters, which is short but contains detailed voting results, not just an announcement of a report. Therefore, it is not a Report Publication Announcement (RPA). The document is not a full annual report, audit report, or management report, nor is it a proxy solicitation or other category. Hence, the correct classification is DVA with high confidence.
2022-06-10 English
10-Q
Interim / Quarterly Report Q1 2022
2022-05-10 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions "Item 2.02 Results of Operations and Financial Condition" and states that the company announced its financial results for the first quarter ended March 31, 2022. It also references a press release as Exhibit 99.1 containing the full text of the announcement. The document is 3603 characters long, which is relatively short and primarily serves to announce the earnings release rather than provide detailed financial statements or analysis. According to the rules, initial announcements of quarterly financial results with key highlights only are classified as Earnings Release (ER). This document fits that description as it announces the first quarter results and includes a press release but does not contain the full detailed financial report itself.
2022-05-10 English
SCHEDULE 13G
Major Shareholding Notification
2022-05-02 English
DEF 14A
Proxy Solicitation & Information Statement
2022-04-26 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.